Skip to main content

Advertisement

Table 1 The IC50 of SFK inhibitors PP1 and PP2 and BCR-Abl kinase/Src kinase inhibitor Dasatinib on a panel of B lymphoma cells of human and murine origin.

From: Anomalous constitutive Src kinase activity promotes B lymphoma survival and growth

  IC50 PP1(μM) PP2 (μM) dasatinib (nM)
Murine lymphoma BKS-2 8.0 7.4 8.3
  WEHI-231 4.6 2.8 17.5
  CH31 6.1 3.6 -
  CH12.Lx 2.5 2.8 7.3
Human lymphoma SudHL-4 1.9 3.1 30
  SudHL-6 6.6 5.2 2.9
  OCI-Ly-3 19.5 12.6 1400
  OCI-Ly-10 3.3 2.0 9.9
  BJAB 4.6 3.4 -
  1. The IC50 was determined using the equation derived from a linear regression of the data.